The overall lower number of fractures in the denosumab group ( 92 ) than in the placebo group ( 176 ) was similar in all patient subgroups , including in patients with a bone mineral density T-score of -1 or higher at baseline ( n = 1872 , HR 044 [ 95 % CI 031-064 ] , p < 00001 ) and in those with a bone mineral density T-score of less than -1 already at baseline ( n = 1548 , HR 057 [ 95 % CI 040-082 ] , p = 0002 ) .